Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial – Fierce Biotech By Weight Loss Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial Fierce Biotech Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo Reuters Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo BioSpace Brought to you by Google News. Read the rest of the article here Facebook Twitter Pinterest